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Australia’s Indigenous people have high rates of chronic
kidney disease and kidney failure. To define renal disease
among these people, we reviewed 643 renal biopsies on
Indigenous people across Australia, and compared them with
249 biopsies of non-Indigenous patients. The intent was to
reach a consensus on pathological findings and terminology,
quantify glomerular size, and establish and compare regional
biopsy profiles. The relative population-adjusted biopsy
frequencies were 16.9, 6.6, and 1, respectively, for Aboriginal
people living remotely/very remotely, for Torres Strait Islander
people, and for non-remote-living Aboriginal people.
Indigenous people more often had heavy proteinuria and renal
failure at biopsy. No single condition defined the Indigenous
biopsies and, where biopsy rates were high, all common
conditions were in absolute excess. Indigenous people were
more often diabetic than non-Indigenous people, but diabetic
changes were still present in fewer than half their biopsies.
Their biopsies also had higher rates of segmental sclerosis,
post-infectious glomerulonephritis, and mixed morphologies.
Among the great excess of biopsies in remote/very remote
Aborigines, females predominated, with younger age at biopsy
and larger mean glomerular volumes. Glomerulomegaly
characterized biopsies with mesangiopathic changes only, with
IgA deposition, or with diabetic change, and with focal
segmental glomerulosclerosis (FSGS). This review reveals great
variations in biopsy rates and findings among Indigenous
Australians, and findings refute the prevailing dogma that
most indigenous renal disease is due to diabetes.
Glomerulomegaly in remote/very remote Aboriginal people is
probably due to nephron deficiency, in part related to low
birth weight, and probably contributes to the increased
susceptibility to kidney disease and the predisposition to FSGS.
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It is well known that Australia’s Indigenous people are
experiencing an epidemic of hypertension, type 2 diabetes,
cardiovascular disease, renal disease, and renal failure.1,2
Renal disease has especially captured attention because of the
high costs of treating subjects with renal replacement therapy
(RRT). It is less well known that disease burden and outcomes
differ markedly among Indigenous people across the country.3–9
Figure 1 is a map of Australia by five categories of
‘remoteness’ as defined by the Accessibility/Remoteness Index
of Australia (ARIAþ ) methodology.10 Most of the interior of
the continent and the north and west are remote or very remote
(R/VR), as are the Torres Strait Islands. Today only about
25% of Indigenous people live in R/VR areas, while most
live in urban or semiurban environments. Although the Torres
Strait Islands are characterized as very remote, many Torres
Strait Islander (TSI) people now live around population centers.
Figure 1 also marks out Australia’s states and territories, which
were constituted without consideration of distribution of
Indigenous people, but which bear most of the responsibility
for, and costs of, RRT for their constituent populations.
Table 1 shows the distribution of the 2006 Indigenous
population by categories of remoteness of their usual place of
residence, and by state/territory.11 New South Wales has the
largest Indigenous population, but most do not live remotely;
Queensland has the next largest Indigenous population but
only 19% live R/VR and almost all the Aboriginal people in
Victoria and Tasmania live near population centers. However,
480% of Aboriginal people in the Northern Territory (NT)
and about 42% in Western Australia live in R/VR areas.
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Assignment of Indigenous status for Australia’s census is
through self report, and it embraces very heterogeneous
populations. Aboriginal people and TSI are distinct groups,
of Micronesian and Melanesian descent, respectively, with
different cultures, lifestyles, diets, body habitus, and health
status. Moreover, mainland Aboriginal Australians are
themselves very heterogeneous in location, languages, non-
Indigenous admixture, lifestyle, socioeconomic status, body
habitus, health, life expectancy, and access to, and utilization
of, services. All documented health parameters, including
birth weights, hospitalization rates, and perinatal, infant and
adult mortality, are worse in mainland Aborigines living in
R/VR areas than in those living less remotely.
Cass et al.12,13 described vast variation by region and
remoteness in the incidence of Indigenous people beginning
RRT from 1993–1998 (Figure 2), and confirmed it again, 10
years later.14 There was a great, though variable, excess in RRT
incidence in Indigenous people in remote and very remote
areas, and much lower rates for those living closer to
population centers. The gradient in RRT correlated strongly
and directly with level of socioeconomic disadvantage, of
which low birth weight is one indicator.13 Variation by
remoteness has more recently been reported by the Australian
Institute of Health and Welfare, from ANZDATA informa-
tion;15 that report also defined an excess of females among
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Figure 1 |Australian Bureau of Statistics, Accessibility/
Remoteness Index of Australia (ARIAþ ). Source: Australian
Bureau of Statistics.10
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Figure 2 | Standardized incidence rates of end-stage renal
disease resulting in renal replacement therapy in Indigenous
Australians in selected regions, 1993–1998. Note: Standardized
incidence ratio. Index population for standardization was the total
Australian resident population. Source: Adapted with permission,
Cass et al.12
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Figure 3 |Two-year rolling average of annual incidence of
end-stage renal disease treated by renal replacement therapy
(RRT) in Indigenous Australians, by state/territory. ACT,
Australian Capital Territory; NSW, New South Wales. Source:
Adapted from McDonald et al.2
Table 1 | Indigenous Australian population, 2006, by states
and territories and remoteness areas, Australian Bureau of
Statistics, ‘Place of Usual Residence’
Population by categories
of remoteness, %
Indigenous
population
Major
city (%)
Inner
regional
(%)
Outer
regional
(%)
Remote
(%)
Very
remote
(%)
New South
Wales
138,057 52.9 33.5 18.5 4.3 0.8
Queensland
Aboriginal
98,305 32.0 22.5 26.5 9.9 9.1
Queensland TSI 18,310 16.3 13.3 34.1 1.5 34.8
Western
Australia
58,476 35.2 8.2 15.0 15.6 26.0
Northern
Territory
53,492 — — 19.5 22.9 57.6
Victoria 30,055 49.2 35.3 15.5 0.1 —
South Australia 25,469 48.9 9.2 23.3 4.2 14.5
Tasmania 16,721 — 53.7 42.7 2.4 1.3
Australian
Capital
Territory
3850 99.8 0.2 — — —
Abbreviation: TSI, Torres Strait Islander.
Source: Adapted from Australian Bureau of Statistics. 2007.11
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incident R/VR Indigenous people, in contrast with the male
excess among non-Indigenous RRT patients.1,15,16
Figure 3 shows the very different RRT incidence rates by
state/territory, ranging from less than twice that of non-
Indigenous Australians (about 110 per million per year) to a
14-fold increase.2 These differential rates, which are directly
linked to RRT treatment costs on a population basis, largely
reflect the different proportions of Indigenous populations
by remoteness of residence, as noted in Table 1.
Awareness of the excess of kidney disease in Aboriginal
people was first heightened in the Top End of the NT and
in Central Australia, and renal biopsies were frequently
performed to define the processes.17,18 A high frequency of
subjectively assessed glomerulomegaly was described, along
with mesangial proliferation and focal sclerosis.17,18 Glomer-
ulomegaly was later confirmed by formal measurements, and
again shown to associate with focal segmental glomerulo-
sclerosis (FSGS).19,20 However, the definition of some of the
Table 2 | Light microscopic data collection items
1 Number of glomeruli in section
2 Mesangial matrix expansion None/mild/moderate/
severe
3 Mesangial hypercellularity None/mild/moderate/
severe
4 Mesangial interposition No/yes
5 Mesangiocapillary change No/yes
6 Glomerular deposits No/yes
Epimembranous No/yes
Intramembranous No/yes
Subendothelial No/yes
Mesangium No/yes
Capillary lumen No/yes
7 Membranous changes No/yes
Holes/spikes/deposits
8 Endocapillary proliferation No/yes
With significant PMNs (43) No/yes
9 Crescents No/yes
In how many glomeruli
Cellular crescents No/yes
In how many glomeruli
Fibrocellular crescents No/yes
In how many glomeruli
Fibrous crescents No/yes
In how many glomeruli
10 Glomerulonecrosis No/yes
11 Glomerular capillary thrombosis No/yes
12 Segmental glomerulosclerosis No/yes
In how many glomeruli
With hyalinosis No/yes
In how many glomeruli
With foam cells No/yes
In how many glomeruli
13 Tip lesions No/yes
In how many glomeruli
With foam cells No/yes
14 Adhesions No/yes
In how many glomeruli
15 Segmental ischaemic glomerulosclerosis No/yes
In how many glomeruli
16 Indeterminate segmental sclerosis No/yes
In how many glomeruli
17 Perihilar sclerosis/adhesions No/yes
In how many glomeruli
With hyalinosis No/yes
18 Collapsing lesion No/yes
In how many glomeruli
19 Glomerular solidification No/yes
In how many glomeruli
20 Glomerular obsolescence No/yes
In how many glomeruli
21 Global glomerulosclerosis with
hyalinosis
No/yes
In how many glomeruli
22 Glomerular infiltration No/yes
In how many glomeruli
Table 2 | Continued
23 Interstitial inflammation None/mild/moderate/
severe
Lympho-histiocytic No/yes
Plasmacytic No/yes
Granulomatous No/yes
Eosinophils No/yes
PMNs No/yes
24 Interstitial fibrosis None/mild/moderate/
severe
25 Interstitial hemorrhage No/yes
26 Periglomerular fibrosis No/yes
In how many glomeruli
27 Fragmentation Bowman’s capsule No/yes
In how many glomeruli
28 Tubulitis None/mild/moderate/
severe
PMNs/lymphocytes/
eosinophils
29 Tubular atrophy None/mild/moderate/
severe
30 Juxtaglomerular apparatus prominent No/yes
31 Intimal fibrosis: interlobular arteries None/mild/moderate/
severe
32 Intimal fibrosis: arcuate arteries None/mild/moderate/
severe
33 Arteriolar hyalinosis None/mild/moderate/
severe
34 Hyalinosis of interlobular arteries None/mild/moderate/
severe
35 Fibrinoid necrosis No/yes
Arterioles/interlobular
arteries
36 Arteriolar thrombosis No/yes
37 Comment: glomerular size Small/normal/large
38 Comments
39 Diagnosis
1
2
3
Abbreviation: PMNs, polymorphonuclear neutrophils.
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morphological features and their relationships to possible
‘diagnoses’ have been uncertain, and practitioners in other
jurisdictions have questioned the applicability of these
findings to the Indigenous populations they serve.
We therefore organized a review of all Indigenous renal
biopsies across Australia. Its objectives were to reach consensus
on pathological findings and terminology, quantify glomerular
size, and establish and compare regional biopsy profiles.
RESULTS
Among 1026 biopsies retrieved and reviewed, 735 were from
indigenous people. Of these, 38 were of transplanted kidneys,
20 were second or subsequent biopsies of kidneys in the same
person, and 24 contained no glomeruli or were otherwise
nonevaluable. The final Indigenous series consisted of 653
eligible biopsies, whose light microscopic findings were
evaluated by our expert panel of nephropathologists (Table 2
and Materials and Methods). Photographs or reports of
immunofluorescent examinations were available for 577, and
497 had electron microscopy studies.
Ten biopsies from Pacific Islanders and 10 of unknown
ethnicity, were excluded. There were 249 evaluable non-
transplant biopsies on non-Indigenous people, described
here; 224 had reports of immunofluorescence, and 240 had
electron microscopy photographs and/or reports.
Table 3 shows the number of evaluable biopsies in
Indigenous people by state/territory, by categories of remote-
ness, and by Aboriginal, TSI, or TSI/Aboriginal designation.
Remoteness classification was lacking for 33. Most biopsies were
from the NT (Top End and Central Australia) and Queensland,
which included all TSI people, with more modest numbers
from Western Australia and South Australia, only five from New
South Wales, and none from the Australian Capital Territory.
Two Indigenous biopsies were identified in Victoria in 2011, but
time did not permit ethics approvals for their inclusion in this
review. Most Aboriginal biopsies were from people living in
R/VR areas, and only 22 were from Aboriginal people living
in or near major cities. There were 73 biopsies from TSI people
and 12 from people of mixed TSI/Aboriginal descent.
Indigenous biopsy findings were analyzed in three groups,
Aboriginal R/VR, Aboriginal non-remote (from major cities,
inner regional areas, and outer regional areas), and as TSI. All
were compared with findings in the non-Indigenous biopsies.
Data from 11 people of mixed TSI/Aboriginal descent, who
had remoteness classification, were included in analyses of
both the Aboriginal and TSI groups, which did not
substantially change the group results.
Figure 4a shows estimates of the population-based
frequencies of biopsies by these categories, using the total
number of biopsies as the numerator and the regional 2006
census populations as denominators. This is not an annual
estimate because biopsies were gathered from 1982 to 2005,
and the Indigenous population has more than doubled over
that interval. Nonetheless, with the same assumptions
applied to each group, the relative ranking is informative.
The figure demonstrates, on an exponential scale, the great
excess of biopsies in people from R/VR areas, and a pre-
dominance of females in that group, while Aboriginal people
Table 3 | The number of evaluable Australian Indigenous
biopsies by state/territory and remoteness and ethnic group
Indigenous Australians by
state/territory N
Indigenous Australians by
remoteness/ethnic
grouping N
Central Australia 210 Very remote Aboriginal 386
Top End Northern Territory 143 Remote Aboriginal 65
Queensland 201 Outer regional Aboriginal 63
Western Australia 54 Inner regional Aboriginal 3
South Australia 40 Major city Aboriginal 19
New South Wales 5 Torres Strait Islander 73
ACT/Victoria/Tasmania 0 Torres Strait Islander/
Aboriginal
12
Abbreviation: ACT, Australian Capital Territory.
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Figure 4 |Ranking of Indigenous renal biopsy frequencies with other measures of renal disease. (a) Biopsy frequency per million
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closer to population centers had much lower biopsy rates
and no female excess. Relative to the population-adjusted
frequency of biopsies in non-remote Aboriginal people, there
was a 6.6-fold greater biopsy frequency in TSI people and a
16.9-fold increase in biopsies from R/VR Aboriginal people.
This ranking is similar to that of RRT incidence rates (Figure 4b).
Rates of overt albuminuria ascertained from limited localized
studies in each region21–24 have similar rankings (Figure 4c).
Table 4 shows some demographic and clinical features of
biopsy subjects. An excess of females among biopsied R/VR
Aboriginal people was confirmed, and was also seen in TSI
people. This contrasts with a male excess in less-remote-
living Aboriginal people, like that in non-Indigenous people.
Median age at biopsy was lowest in R/VR Aboriginal people,
and in TSI and non-remote Aboriginal people was more like
those of non-Indigenous people. Indigenous people were
Table 4 | Characteristics of persons in the biopsy series and features of their biopsies
Non-Indigenous
Aboriginal
non-remotea
Torres Strait
Islander
Aboriginal
remote/very
remote
Non-Indigenous
vs Indigenous
Aboriginal
remote/very
remote vs other
Indigenous
N=249 N=92 N=84 N=455 Pb Pb
Demographic and clinical features
Female, % 40.2 46.7 56.0 55.4 o0.001 0.337
Age, years, mean (s.d.) 45.2 (16.6) 43.3 (14.4) 45.6 (15.8) 39.2 (13.9)c 0.0002b 0.0001b
Known diabetes, % 14.6 48.3 42.9 42.4 o0.001 0.459
Proteinuriad, % 67.5 77.5 71.4 85.5 o0.001 0.001
Heavy proteinuriae, % 22.2 33.7 36.9 43.2 o0.001 0.073
Renal insufficiencyf, % 43.2 59.6 61.9 54.2 0.001 0.144
Renal failureg, % 16.6 32.6 33.3 22.5 0.006 0.007
Morphologic features
Glomerular profiles per biopsy, median
(IQR)
15 (10–24) 14 (9–20) 15 (8–23) 14 (8–22) 0.0405 0.5951b
Mean glomerular volumeh, mm3 106,
mean (95% confidence interval)
2.57 (2.4–2.8) 2.54 (2.2–2.9) 2.47 (2.2–2.8) 3.78 (3.6–4.0) o0.0001b o0.0001b
Mesangiopathic change, % 84.3 94.6 94.1 92.8 o0.001 0.483
Segmental sclerosis, % 45.8 56.5 57.1 63.3 o0.001 0.134
Crescents, % 13.4 18.7 14.8 10.9 0.741 0.046
Percentage of glomeruli per biopsy, with
crescents, median (IQR)
16.7 (5.3–46) 16.7 (8.3–28.0) 10.4 (8.0–33.0) 13.8 (8.7–33.3) 0.388b 0.316b
Interstitial inflammation/fibrosis, % 88.7 94.4 91.5 91.2 0.167 0.449
Vascular change, % 72.7 81.5 82.1 79.1 0.021 0.449
End-stage kidney, % 0.4 4.4 1.2 1.5 0.125 0.330
Assessments/diagnosesi
Diabetic nephropathy, % 8.4 41.3 48.8 26.6 o0.001 o0.001
Focal segmental glomerulosclerosis, % 16.1 12.0 9.5 19.6 0.707 0.009
Mesangiopathic GNj, % 13.7 6.5 6.0 14.2 0.769 o0.001
IgA nephropathy, % 24.4 19.1 18.2 12.7 0.001 0.067
Diffuse proliferative GN 9.6 12.0 8.3 5.9 0.213 0.060
Post-infectious GN, % 1.6 8.7 11.9 5.9 0.001b 0.060
Interstitial nephritis, % 9.2 4.4 2.4 4.4 0.003 0.576
Membranoproliferative GN, % 3.6 3.3 3.6 4.0 0.894 0.747
Amyloidosis, % 0.8 0.0 0.0 3.7 0.120b 0.005b
Lupus nephritis, % 6.4 5.4 2.4 3.7 0.093 0.887
Hypertensive renal disease, % 4.0 6.5 6.0 2.9 0.883 0.046
Minor change only, % 4.4 0 2.4 2.0 0.022 0.469
Membranous GN, % 6.8 5.4 1.2 1.5 o0.001 0.138
Two or more diagnosesk, % 5.6 12.0 20.2 9.7 0.009 0.027
Two or more diagnosesk, major groupsl, % 1.2 7.6 13.1 7.0 o0.001 0.183
Abbreviations: GN, glomerulonephritis; IQR, interquartile range.
aNon-remote: Major city, inner regional, and outer regional place of residence.
P: T-test/w2 test.
bT-test unequal variance option or Fisher’s exact test.
cR/VR Aboriginals were significantly younger than all others biopsied, Po0.0001.
dProteinuria: albumin creatinine ratio X34 g/mol or protein creatinine ratio X50 g/mol or dipstick protein: X1+ or X0.15 g/day or X0.15 g/l, or stated in history.
eHeavy proteinuria: albumin creatinine ratio X300 g/mol or urinary protein: dipstick X3+ or X3 g/day or X3 g/l, or stated in history.
fRenal impairment: S-creatinine: 4106 mmol/l if female or 4120 mmol/l if male, or stated in history.
gRenal failure: S-creatinine X400 mmol/l or stated in history.
hEnd-stage kidneys excluded.
iIn addition, there were five cases of reflux nephropathy in remote/very remote Aboriginal (1.1%), as well as rare cases of light chain disease 3 (0.7%), Henoch–Scho¨nlein purpura
0, pyelonephritis 6 (01.3%), thrombotic thrombocytopenic purpura 3 (0.7%) and vasculitis 1 (0.2%), arteriolar nephrosclerosis 20 (4.4%), and acute tubular necrosis 1 (0.2%).
jMesangiopathic GN, with or without immune complexes but excluding IgA nephropathy or focal segmental glomerulosclerosis.
kTwo or more assessments/diagnoses. Note: secondary focal segmental glomerulosclerosis not counted as a separate diagnosis.
lTwo or more diagnoses: major groups, diabetic nephropathy and post-infectious GN, diabetic nephropathy and IgA nephropathy, diabetic nephropathy and interstitial nephritis,
and diabetic nephropathy and diffuse proliferative GN.
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more frequently identified as diabetic at the time of
biopsy. They more often had nephrotic range proteinuria,
renal insufficiency, and renal failure at biopsy than non-
Indigenous people.
Table 4 also shows some of the light microscopic
morphological biopsy features. The median number of
glomerular profiles per biopsy was about 14. The measured
average glomerular tuft volume in non-end-stage kidneys was
significantly larger in R/VR Aboriginal people than in the
other three groups. The values were unchanged when
restricted to biopsies with X4 glomerular profiles (95% of
non-Indigenous and 91% of Indigenous biopsies).25 Almost
all Indigenous biopsies had mesangiopathic change (Table 2,
including items no. 2, no. 3) and more often had segmental
glomerular tuft sclerosis (items no. 12–18) than non-
Indigenous biopsies. Most biopsies had interstitial inflam-
mation and fibrosis with tubular atrophy and loss (items no.
23, no. 24, no. 28, no. 29). Crescents, largely cellular and
fibrocellular, were present in substantial proportions of
biopsies, and involved more than 10% of glomeruli (item
no. 9). Most had vascular changes (items no. 31–35).
Indigenous people more often had end-stage kidneys at
biopsy.
The table also shows the final assessments, derived from
the experts reviewers’ ‘diagnoses’ and the final collation of
individual morphological variables. Leading assessments
among R/VR Aboriginal biopsies were diabetic change,
mesangiopathic glomerulonephritis (GN) (without IgA),
and IgA nephropathy. Indigenous biopsies more often had
diabetic changes, with the highest proportions in non-remote-
living Aborigines and TSI. However, diabetic change was
found in fewer than half the Indigenous biopsies. The
proportion of biopsies with a diagnosis of FSGS was highest
in biopsies from R/VR Aboriginal people. IgA nephropathy
was well represented in all the indigenous groups, although
in lower absolute proportions for R/VR Aboriginal people,
among whom 14% had crescents. Substantial numbers of
Indigenous people had diffuse proliferative GN (40–60% with
crescents), which included much higher proportions with
post-infectious GN. The constitution of the infiltrates
associated with interstitial nephritis was similar in all groups:
with lymphocytic/histiocytic cells always present, while about
50% also had plasma cells, and about 30% had eosinophils/
polymorphonuclear cells. Sixteen Indigenous people, all from
R/VR areas, had amyloid in their kidney biopsies, which,
when (infrequently) specified, was the amyloid light chain
type. The proportions with membranous GN were lower in
the R/VR Aboriginal series and TSI biopsies than in non-
Indigenous biopsies. Indigenous people had higher propor-
tions of biopsies with multiple ‘diagnoses’, excluding cases of
secondary FSGS with a specified underlying condition, of
which most fell into four major categories—diabetic nephro-
pathy plus post-infectious GN (n¼ 21), diabetic nephropathy
plus IgA nephropathy (n¼ 13), diabetic nephropathy plus
interstitial nephritis (n¼ 10), and diabetic nephropathy plus
diffuse proliferative GN (n¼ 6).
Figure 5 demonstrates the higher mean glomerular
volumes (MGV) in biopsies of R/VR Aboriginal people
compared with the other study groups. Figure 6 shows that
among mutually exclusive groups of ‘diagnoses’ in non-end-
stage kidneys in R/VR Aboriginal people, average mean
glomerular volumes in decreasing rank order were mesangio-
pathic changes alone, FSGS (with similar values for secondary
and primary forms: means 4.1, confidence interval 3.5–4.7 vs
3.8, confidence interval 3.1–4.5) and diabetic nephropathy.
The average MGV was also elevated in people with IgA
nephropathy without FSGS, but the numbers were smaller.
Table 5 shows that, with retrospective application of the
2010 classification of Thijs et al.,26 the major classes of
diabetic nephropathy in all subjects groups were severe
mesangial expansion (Class IIB) and advanced diabetic
sclerosis (Class IV), with substantial proportions with
diabetic nodular sclerosis.
Table 6 and 7 show classifications of FSGS.27 Cases of
secondary FSGS, further defined in the legend of the table,
outnumbered apparent primary FSGS in Indigenous people.
The major histological category in both primary and
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Table 5 | Diabetic nephropathy classification in the biopsy series26
Class Diabetic nephropathy classification
Non-Indigenous
(N=21)
Aboriginal
non-remotea (N=38)
Torres Strait
Islander (N=41)
Aboriginal
remote/very remote
(N=121)
I Mild or non-specific LM changes and EM-proven GBM thickening 1 (4.8%) 0 0 0
IIA Mild mesangial expansion 2 (9.5%) 2 (5.3%) 5 (12.2%) 15 (12.4%)
IIB Severe mesangial expansion 9 (42.9%) 13 (34.2%) 14 (34.2%) 58 (47.9%)
III Nodular sclerosis (Kimmelstiel–Wilson lesion) 4 (19.1%) 7 (18.4%) 6 (14.6%) 14 (11.6%)
IV Advanced diabetic glomerular sclerosis 5 (23.8%) 16 (42.1%) 16 (39.0%) 34 (28.1%)
Abbreviations: EM, electron microscopy; GBM, glomerular basement membrane; LM, light microscopy.
aNon-remote: major city, inner regional, and outer regional place of residence.
Table 6 | Classification of focal segmental glomerular sclerosis in the biopsy series
Classification and class Non-Indigenous
Aboriginal
non-remotea
Torres Strait
Islander
Aboriginal
remote/very remote
Aetiologic
Primary FSGS 17 (6.8%) 5 (5.4%) 2 (2.4%) 29 (6.4%)
Secondary FSGS 23 (9.2%) 6 (6.5%) 6 (7.1%) 60 (13.2%)
Histologicb
Primary FSGS N=17 N=5 N=2 N=29
Not otherwise specified 14 (82.4%) 5 (100.0%) 2 (100.0%) 15 (51.7%)
Perihilar variant 2 (11.8%) 0 0 12 (41.4%)
Tip variant 1 (5.9%) 0 0 0
Collapsing variant 0 0 0 1 (3.5%)
Cellular variant 0 0 0 1 (3.5%)
Secondary FSGS N=23 N=6 N=6 N=60
Not otherwise specified 13 (56.52%) 5 (83.3%) 4 (66.7%) 38 (63.3%)
Perihilar variant 9 (39.1%) 1 (16.7%) 2 (33.3%) 18 (30.0%)
Tip variant 0 0 0 1 (1.7%)
Collapsing variant 0 0 0 1 (1.7%)
Cellular variant 1 (4.35%) 0 0 2 (3.3%)
Abbreviation: FSGS, focal segmental glomerulosclerosis.
aNon-remote: major city, inner regional, and outer regional place of residence.
bThe Columbia classification.27
An assignment of secondary FSGS was given if any of the following clinical-pathologic conditions were present: diabetes mellitus, diabetic nephropathy, IgA nephropathy,
lupus nephritis, thin membrane nephropathy, immune complex glomerulonephritis, pyelonephritis, reflux nephropathy, familial nephritis, or morbid obesity. The remaining
biopsies were assigned as primary FSGS.
Table 7 | Clinical correlates of FSGS in the biopsy series
Correlate, %
Non-
Indigenous
Aboriginal
non-remote*
Torres Strait
Islander
Aboriginal
remote/very
remote
Non-Indigenous vs
Indigenous
Aboriginal remote/very
remote vs other
Indigenous
Primary FSGS N=17 N=5 N=2 N=29
Proteinuriaa 60.0 60.0 100.0 89.7 0.061b 0.244b
Heavy proteinuriac 40.0 20.0 100.0 51.7 0.554b 1.00b
Renal impairmentd 46.7 60.0 50.0 44.8 0.971 0.684b
Renal failuree 20.0 0 0 3.5 0.071b 1.00b
Secondary FSGS N=23 N=6 N=6 N=60
Proteinuriaa 59.1 83.3 83.3 93.3 0.002b 0.260b
Heavy proteinuriac 22.7 33.3 0 45.0 0.204b 0.106b
Renal impairmentd 31.8 66.7 16.7 40.0 0.475 1.00b
Renal failuree 4.6 33.3 0 13.3 0.448b 0.669b
Abbreviations: FSGS, focal segmental glomerulosclerosis; IQR, interquartile range.
aProteinuria: albumin creatinine ratio X34 g/mol or protein creatinine ratio X50 g/mol or dipstick protein X1+ or X0.15 g/day or X0.15 gm/l, or stated in history.
bFisher’s exact test.
cHeavy proteinuria: albumin creatinine ratio X300 g/mol or urinary protein: dipstick X3+ or X3 g/day or X3 g/l, or stated in history.
dRenal impairment: S-creatinine: 4106 mmol/l if female or 4120 mmol/l if male, or stated in history.
eRenal failure: S-creatinine X400 mmol/l or stated in history.
P: w2 test.
*Non-remote: major city, inner regional, and outer regional place of residence.
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secondary forms was the unspecified type, followed by the
perihilar variant.
Applying the proportions of diagnoses/assessments to the
relative frequencies of biopsies on a population basis, there
was a great excess of most leading biopsy findings among
R/VR Aborigines, and a considerable excess in TSI people, as
shown in Figure 7.
DISCUSSION
This is the first nationwide perspective on renal biopsies in
Australian Indigenous people. It shows marked heterogeneity
of biopsy rates among them, and similarities as well as
differences in morphological findings. Among R/VR Abori-
ginal people, there was a striking relative and absolute excess
of biopsies, a female predominance, a younger age at biopsy,
and larger glomeruli, compared with other Indigenous as well
as non-Indigenous biopsies. There was a relative excess of
biopsies in TSI people and a female predominance, but an
older age at biopsy. Among the many fewer non-remote
Aboriginal people with biopsies, there was no female excess
and their ages at biopsy were higher, both more aligned to the
non-Indigenous biopsy series.
The biopsy frequencies and gender distributions among
the Indigenous groups approximately parallel their RRT rates
and patterns. They are also compatible with community-
based distributions of overt albuminuria found in a very
limited number of localized studies in the relevant groupings,
(all of which contrast with 0.6% prevalence in adult non-
Indigenous Australians, without a female dominance).28
These are reassuring synergies between community-based
disease frequency, biopsy rates, and terminal renal failure.
The absolute numbers and the population-based rates of
biopsies in the states and territories reflect to a large extent
the characteristics of their Indigenous populations and the
variations of the distributions of their Aboriginal people by
remoteness. This helps explain the different impressions of
nephrologists in the various states/territories about the
frequency and nature of renal disease they see in Indigenous
people.
All the usual changes and ‘diagnoses’ were represented in
Indigenous people in this biopsy series. Notable in all three
Indigenous groups were the high, though variable, propor-
tions of diabetics, more advanced renal disease at biopsy,
their higher frequency of diabetic nephropathic changes, of
segmental glomerular tuft injury, and of post-infectious GN.
Proportions of biopsies with IgA nephropathy, other forms of
mesangiopathic GN, and membranous GN were not higher
in R/VR Aboriginal and TSI biopsies than in non-Indigenous
people. However, as we have emphasized (Figure 7), wherever
the renal disease burden and the biopsy rates are high, the
absolute number of biopsies with any finding of substantial
frequency represents a population-based excess.
We cannot comment on genetic determinants of renal
disease among Indigenous people, although genomic studies
have begun. However, the major drivers of excess renal
disease are potentially modifiable risk factors, such as
intrauterine growth retardation and low birth weight, poor
nutrition in infancy, childhood, and adult life, high levels of
adult body mass index and diabetes, and the burden of
infections and inflammation.29–31 These are generally worse
in Aborigines from R/VR areas: e.g., the frequency of low
birth weight is still increased 2–3-fold,32 and, in the NT, was
present in about one-third of births 40 years ago,30,31,33 when
susceptibility was established in current biopsy subjects. Non-
remote Indigenous people have higher birth weights, though
still about 100 g short of the non-Indigenous Australian
norm,32 and high levels of diabetes,21 while TSI people have
largely normal birth weights,9 but very high levels of adult
obesity and diabetes.9,22
Our findings support the high frequency of glomerulo-
megaly previously documented in Aboriginal biopsies from
Top End NT19 and extend the observation to other
Aborigines in R/VR areas, as described by subjective
assessments many years ago.17 Specific proliferative diseases
aside, glomerular enlargement is thought to be driven by
compensatory hypertrophy in the setting of lower nephron
numbers and/or by other hypertrophic stimuli such as
overweight or obesity, the metabolic syndrome, and diabetes
and perhaps inflammation.34 We recently described enlarged
glomeruli at autopsy in kidneys of people without obvious
renal disease, in the presence of lower nephron number, low
birth weight, and obesity.34–39 Furthermore, in that autopsy
series, we found that R/VR Aboriginal people without renal
disease had, on average, lower nephron numbers and higher
glomerular volumes than regional non-Aboriginal controls, a
difference that was probably driven by the lower birth weights
of the Aboriginal group.40 We have also described an
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Figure 7 | Estimated relative frequency of biopsy assessments
per million population. FSGS, focal segmental
glomerulosclerosis; GN, glomerulonephritis; R/VR, remote or very
remote living; TSI, Torres Strait Islander. Source: Denominator,
Australian Bureau of Statistics.11
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association of lower birth weights with renal disease in the R/
VR community setting.30,31 Thus glomerulomegaly in
biopsied R/VR Aboriginal people probably represents com-
pensatory hypertrophy in the presence of congenital
nephronopenia related to low birth weight and intrauterine
growth restriction, with variable superimposition of postnatal
effects of body size, metabolic disorders, and infection/
inflammation. This is compatible with Brenner’s nephro-
pathy of oligonephronia in a multideterminant or ‘multihit’
model of renal disease in a high-risk environment.41,42
Obesity is less likely to be a primary driver of glomerulo-
megaly in this setting, for in some R/VR communities rates
of overweight and obesity are considerably below those for
non-Indigenous Australians.43,44 Nephron deficiency is less
likely to contribute to glomerulomegaly and renal disease in
non-remote Aboriginal people and still less in TSI people,
who have higher birth weights, but higher rates of over-
weight, diabetes, and the metabolic syndrome.
The association of glomerular enlargement with FSGS
demonstrated in the R/VR Aboriginal groups is also
consistent with our previous observation in a smaller number
of Top End Aboriginal biopsies.20 Hughson et al.45 have
described a similar sequence with FSGS in biopsies of African
Americans. Glomerular tuft injury might be mediated
through deficient podoctye coverage of glomerular basement
membrane as glomeruli enlarge, as observed in a model of
nephronopenia by Kriz,46 with the largest volumes, demon-
strated in biopsies with mesangial change only, representing
the earliest phase of injury, and FSGS a more advanced stage.
We suggest that glomerular enlargement underlies excessive
susceptibility to injury in the presence of other predisposing
factors. Glomerulomegaly and its accompaniments will be
further addressed in subsequent manuscripts.
Excess renal disease in Indigenous Australians is com-
monly attributed to type 2 diabetes.2 However, fewer than
half the Indigenous biopsy subjects were recorded as diabetic
at biopsy, and not all their biopsies showed diabetic change.
In fact, among the great excess of biopsies among R/VR
Aboriginal people, only one quarter had definitive diabetic
change. Although rates of diabetes are high, and many
Indigenous people have acquired the diagnosis by age of
45 years, such a history does not mean that diabetic nephro-
pathy is the primary cause of renal disease in a given patient.
In fact, community-based studies in R/VR Indigenous people
that show substantial prevalence of proteinuria in people
without diabetes,21,22,29,47 demonstrate that proteinuria/
albuminuria appear at higher rates and earlier in life than
diabetes,47,48 and predict, often by many years, the later
development of diabetes.49 Thus, albuminuria seems to be
part of the hemodynamic/metabolic/renal syndrome, of which
diabetes is a later and variable element. We acknowledge,
however, that most diabetic patients with a clinical picture
compatible with diabetic nephropathy do not undergo renal
biopsies to confirm a diagnosis, and concede that diabetes
facilitates and accelerates progression of kidney disease of
most causes.
High levels of immune complex and post-infectious
disease are compatible with the persistent and recurrent
infections and the elevated inflammatory markers in these
environments.23,50–53 Excessive accumulation of immune
complexes and other deposits and/or their defective clearance
could also contribute to, or result from, the mesangiopathy
that accompanies glomerular enlargement, at least in the
nephron deficiency model.46
The female excess in renal disease, seen in the RRT
population, in community screening programs and now in
biopsies in R/VR Aboriginal and TSI people, is not completely
understood. Partial explanations might lie in the lower
nephron endowment in females (about 17% fewer ne-
phrons54), their lower birth weights, higher body mass
indexes, and greater central fat deposition, higher rates of
diabetes until mid life, and perhaps the effects of pregnancy.
There are many limitations to this study. The consolidation
of non-remote Aboriginal people into only one category
obscures potential additional differences. Deficient Indigen-
ous assignment could influence case ascertainment, as well as
population denominators. Nephrologists’ recall is undoubtedly
incomplete, and the designation of ‘at least half Indigenous’
(see Methods) is precarious. Furthermore, levels of awareness
and ascertainment of preterminal renal disease have varied
by region and over time, as have availability of nephrology
expertise and philosophies about biopsies. For example, the
first spate of biopsies in the Top End of the NT was driven by
need to define the lesions. More recently, biopsies have often
been limited to people in whom unusual findings might
change management, beyond general renal protection and
metabolic and blood pressure control. And, as already noted,
diabetics with renal disease are usually not biopsied.
Nonetheless important facts are exposed for the first time
by this series. The variations in biopsy rates and findings
resonate with the population-based variations in clinical
renal disease in Indigenous people across the country. These
are probably explained by regional differences in stages in the
epidemiological and health transitions, in environmental and
socioeconomic circumstances and in genotype and genetic
admixture, and are expressed in variable accentuation of fre-
quency of most of the common or garden variety of renal
morphologic changes. The greatest absolute reduction in clinical
renal disease and RRT will be through intensive targeting of
risk factors in R/VR Aboriginal people and in TSI people.
MATERIALS AND METHODS
All nephrologists in Australia were invited to participate, through
identification of Indigenous people who had undergone kidney
biopsy and through participation in biopsy reviews. The major
pathology laboratories in each region were likewise requested to
identify Indigenous renal biopsies where possible. Ethical review
boards at each clinical center and laboratory, as well as the
participating academic centers, and their Indigenous subcommit-
tees, approved the study.
The review was restricted to people considered to be at least half
Indigenous. Slides from contemporaneous biopsies on non-Indigen-
ous people were also retrieved in an approximate ratio of one per three
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Indigenous biopsies. Demographic data were derived from hospital
databases or biopsy referral forms. Clinical summaries were taken
from biopsy referral sheets; the detail was sometimes very deficient.
The expert review group consisted of five international
nephropathologists (ABF, JPD, MDH, PSK-S, and RS). They, and
other interested persons, met for 4-week-long meetings over a period
of 3 years. A data collection form (Table 2) was developed through a
process of progressive modification as findings dictated. The panel,
initially blinded to ethnicity, demographic and clinical history of
the biopsied subjects, recorded findings on light microscopic review
of the slides, and their tentative assessments. The reviews were
conducted either in committee or discussed by the whole committee
following review by individual experts. The panel later reviewed their
assessments as photographs and reports of immunofluorescence and
electron microscopy studies became available. The presence,
localization, and nature of immune complex deposits were
determined and glomerular basement membranes examined. Finally,
diagnoses were refined in the context of an individual’s information
from all sources, including available clinical data.
In a subsequent phase, glomerular tuft and corpuscle volumes in
each biopsy were estimated, as previously described,19 through
application of the Weibel and Gomez formula to the average
measurement of the areas of all available glomerular profiles on a
given section. Later steps included formal measurement of
glomerular sclerotic index, interstitial fibrosis, and glomerular
basement membrane thickness, with techniques and the findings
described in later manuscripts.
Statistical analyses were conducted using Stata Statistical Soft-
ware: Release 11 (StataCorp, College Station, TX). Summary data
are presented as means with s.d.’s or as category percentages. Means
were compared using the t-test, accounting for unequal variance as
necessary. Proportions were compared using the w2 or the Fisher’s
exact tests.
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